Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRENT M SCHILLINGER

Allopathic & Osteopathic Physicians Dermatology

NPI
1457332488
CMS profile
20970
Location
DELRAY BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$54.71

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $54.71 3

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
UCB, Inc. $21.58 1
Janssen Biotech, Inc. $16.73 1
AbbVie, Inc. $16.40 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRENT M SCHILLINGER

NPI 1457332488 · CMS profile ID 20970

Allopathic & Osteopathic Physicians / Dermatology

DELRAY BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457332488?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRENT M SCHILLINGER, NPI 1457332488, CMS profile ID 20970. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457332488?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BRENT M SCHILLINGER, NPI 1457332488, CMS profile ID 20970. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457332488?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BRENT M SCHILLINGER, NPI 1457332488, CMS profile ID 20970, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1457332488?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $54.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $16.4010/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648020577 CMS
UCB, Inc. $21.5810/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688311725 CMS
Janssen Biotech, Inc. $16.7302/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658695787 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $54.71 3
PY2021 $30.38 2
PY2022 $508.95 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $141,565.48 113
PY2024 Principal investigator $443,824.85 219
PY2023 Recipient $2.02 1
PY2023 Principal investigator $20,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

113 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $16,600.00 12/31/2025 Non-covered Recipient Entity
DH Tamarac Research Center LLC
A PHASE 2 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB PF06651600 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1228744491
Principal investigator 1 SANOFI PASTEUR INC. $15,000.00 10/30/2025 Non-covered Recipient Entity
Elias Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226109054
Principal investigator 1 PFIZER INC. $12,000.00 10/29/2025 Non-covered Recipient Entity
DH Tamarac Research Center LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228755236
Principal investigator 1 SANOFI US SERVICES INC. $33,910.00 07/28/2025 Non-covered Recipient Entity
Dorisca Research Consulting Inc
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226096859
Principal investigator 1 Eli Lilly and Company $2,000.00 05/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187879897
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200120
Principal investigator 1 Janssen Research & Development, LLC $438.01 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200127
Principal investigator 1 Janssen Research & Development, LLC $442.19 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200137
Principal investigator 1 Janssen Research & Development, LLC $329.13 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200151
Principal investigator 1 Janssen Research & Development, LLC $466.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200159
Principal investigator 1 Janssen Research & Development, LLC $59.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200165
Principal investigator 1 Janssen Research & Development, LLC $208.84 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200183
Principal investigator 1 Janssen Research & Development, LLC $59.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200192
Principal investigator 1 Janssen Research & Development, LLC $439.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200202
Principal investigator 1 Janssen Research & Development, LLC $197.84 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200210
Principal investigator 1 Janssen Research & Development, LLC $59.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200219
Principal investigator 1 Janssen Research & Development, LLC $208.84 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200229
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200239
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200246
Principal investigator 1 Janssen Research & Development, LLC $271.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200255
Principal investigator 1 Janssen Research & Development, LLC $59.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200265
Principal investigator 1 Janssen Research & Development, LLC $130.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200273
Principal investigator 1 Janssen Research & Development, LLC $329.13 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200287
Principal investigator 1 Janssen Research & Development, LLC $271.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200308
Principal investigator 1 Janssen Research & Development, LLC $438.01 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200324
Principal investigator 1 Janssen Research & Development, LLC $59.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200331
Principal investigator 1 Janssen Research & Development, LLC $59.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200340
Principal investigator 1 Janssen Research & Development, LLC $208.84 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200348
Principal investigator 1 Janssen Research & Development, LLC $197.84 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200375
Principal investigator 1 Janssen Research & Development, LLC $279.25 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200395
Principal investigator 1 Janssen Research & Development, LLC $59.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200402
Principal investigator 1 Janssen Research & Development, LLC $442.19 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200420
Principal investigator 1 Janssen Research & Development, LLC $337.10 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200426
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200440
Principal investigator 1 Janssen Research & Development, LLC $337.10 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200449
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200470
Principal investigator 1 Janssen Research & Development, LLC $59.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200478
Principal investigator 1 Janssen Research & Development, LLC $329.13 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200483
Principal investigator 1 Janssen Research & Development, LLC $129.87 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200495
Principal investigator 1 Janssen Research & Development, LLC $173.20 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200503
Principal investigator 1 Janssen Research & Development, LLC $439.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200510
Principal investigator 1 Janssen Research & Development, LLC $130.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200518
Principal investigator 1 Janssen Research & Development, LLC $271.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200525
Principal investigator 1 Janssen Research & Development, LLC $279.25 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200533
Principal investigator 1 Janssen Research & Development, LLC $279.25 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200555
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200561
Principal investigator 1 Janssen Research & Development, LLC $439.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200578
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200600
Principal investigator 1 Janssen Research & Development, LLC $279.25 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200609
Principal investigator 1 Janssen Research & Development, LLC $337.10 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200617
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200624
Principal investigator 1 Janssen Research & Development, LLC $173.20 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200646
Principal investigator 1 Janssen Research & Development, LLC $375.64 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200659
Principal investigator 1 Janssen Research & Development, LLC $130.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200677
Principal investigator 1 Janssen Research & Development, LLC $329.13 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200684
Principal investigator 1 Janssen Research & Development, LLC $279.25 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200693
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200699
Principal investigator 1 Janssen Research & Development, LLC $173.20 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200727
Principal investigator 1 Janssen Research & Development, LLC $208.84 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200733
Principal investigator 1 Janssen Research & Development, LLC $271.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200740
Principal investigator 1 Janssen Research & Development, LLC $329.13 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200749
Principal investigator 1 Janssen Research & Development, LLC $197.84 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200757
Principal investigator 1 Janssen Research & Development, LLC $271.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200769
Principal investigator 1 Janssen Research & Development, LLC $197.84 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200779
Principal investigator 1 Janssen Research & Development, LLC $279.25 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200785
Principal investigator 1 Janssen Research & Development, LLC $197.84 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200793
Principal investigator 1 Janssen Research & Development, LLC $173.20 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200800
Principal investigator 1 Janssen Research & Development, LLC $208.71 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200808
Principal investigator 1 Janssen Research & Development, LLC $279.25 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200816
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200824
Principal investigator 1 Janssen Research & Development, LLC $466.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200858
Principal investigator 1 Janssen Research & Development, LLC $129.87 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200866
Principal investigator 1 Janssen Research & Development, LLC $59.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200891
Principal investigator 1 Janssen Research & Development, LLC $271.96 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200904
Principal investigator 1 Janssen Research & Development, LLC $59.00 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200914
Principal investigator 1 Janssen Research & Development, LLC $375.64 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200935
Principal investigator 1 Janssen Research & Development, LLC $337.10 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200944
Principal investigator 1 Janssen Research & Development, LLC $122.04 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200952
Principal investigator 1 Janssen Research & Development, LLC $442.19 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200969
Principal investigator 1 Janssen Research & Development, LLC $173.20 05/12/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200999
Principal investigator 1 Eli Lilly and Company $14,410.00 04/03/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR No dispute reported 06/30/2026 1187880559
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143323
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143327
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143331
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143335
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143342
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143347
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143351
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143355
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143360
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143365
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143369
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143578
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143582
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143585
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143590
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143594
Principal investigator 1 SANOFI US SERVICES INC. $650.00 03/20/2025 Non-covered Recipient Entity
Dorisca Research Consulting Llc
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1226143598
Principal investigator 1 Janssen Research & Development, LLC $722.25 03/07/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200280
Principal investigator 1 Janssen Research & Development, LLC $4,399.65 03/07/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200357
Principal investigator 1 Janssen Research & Development, LLC $175.00 03/07/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200367
Principal investigator 1 Janssen Research & Development, LLC $175.00 03/07/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200408
Principal investigator 1 Janssen Research & Development, LLC $726.30 02/13/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200539
Principal investigator 1 Janssen Research & Development, LLC $726.30 02/13/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200595
Principal investigator 1 Janssen Research & Development, LLC $175.00 02/13/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200632
Principal investigator 1 Janssen Research & Development, LLC $726.30 02/13/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200667
Principal investigator 1 Janssen Research & Development, LLC $175.00 02/13/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200882
Principal investigator 1 Janssen Research & Development, LLC $175.00 02/13/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200992
Principal investigator 1 Janssen Research & Development, LLC $900.00 01/06/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200144
Principal investigator 1 Janssen Research & Development, LLC $500.00 01/06/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200300
Principal investigator 1 Janssen Research & Development, LLC $1,800.00 01/06/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200831
Principal investigator 1 Janssen Research & Development, LLC $5,850.00 01/06/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200961
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 01/06/2025 Non-covered Recipient Entity
Dev and H Tamarac Rsrch Ctr Llc
A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis No dispute reported 06/30/2026 1175200976